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Microsatellite DNA polymorphism of human adrenomedullin Adrenomedullin (AM) is a hypotensive peptide pro-
gene in type 2 diabetic patients with renal failure. duced in cardiovascular tissues such as heart, lung, kid-
Background. Adrenomedullin (AM) is a hypotensive pep- ney, and vascular wall [1, 2]. Besides the potent vasodila-tide widely produced in the cardiovascular organs and tissues
tor action, AM has also been shown to cause natriuresissuch as the heart, kidney, and the vascular cells. We have pre-
in the kidney [3]. A significant level of AM has been alsoviously cloned and sequenced the genomic DNA encoding hu-
man AM gene, and determined that the gene is located in the identified in human plasma [1, 4] and we have previously
short arm of chromosome 11. The 3-end of the gene is flanked reported that plasma AM levels are increased in patients
by the microsatellite marker of cytosine adenine (CA) repeats. with renal failure and hypertension [5]. Moreover, it has
In this study, we investigated the association between DNA
been recently reported that gene delivery or chronicvariations in AM gene and the predisposition to develop ne-
administration of AM alleviates renal injuries in hyper-phropathy in type 2 diabetes mellitus.
Methods. Genomic DNA was obtained from the peripheral tensive rats [6–10]. These findings suggest that AM has
leukocytes of 233 normal healthy subjects (NH), 139 type 2 implications in pathophysiology of the renal diseases.
diabetic patients on hemodialysis (DM-HD), 106 control pa- We have cloned and sequenced the genomic DNA
tients with type 2 diabetes without nephropathy (DM-C) and encoding human AM gene, and determined that the gene318 hemodialysis patients due to chronic glomerulonephritis
is located in the short arm of chromosome 11 [11]. The(CGN-HD). The genomic DNA was subject to polymerase chain
gene consists of four exons and whole nucleotide se-reaction (PCR) using a fluorescence-labeled primer, and the
number of CA repeats were determined by polyacrylamide gel quence corresponding to the 52 amino acid residues of
electrophoresis (PAGE). mature AM is included in the fourth exon. Nucleotide
Results. In our Japanese subjects, there existed four types sequencing of genomic DNA adjacent to the AM geneof alleles with different CA-repeat number; 11, 13, 14, and 19.
revealed that the 3-end of the gene is flanked by theThe frequencies of these alleles were 11: 27.7%, 13: 32.8%, 14:
microsatellite marker with a variable number of cytosine35.6%, and 19: 3.9% in NH. These allele frequencies were
not significantly different in DM-C and CGN-HD. However, adenine (CA) repeat [12]. This microsatellite marker is
DM-HD showed significantly different distribution of allele located approximately 4 kb downstream of the AM gene.
frequency from other groups (2  18.9, P  0.026). Namely, Considering the possible implications of AM in the car-
the frequency of 19-repeat allele in DM-HD was higher (9.0%)
diovascular system, it seems of interest to elucidatethan NH, DM-C, and CGN-HD (P  0.005, 0.041, and 0.004,
whether this gene variation has any relation to the etiol-respectively).
Conclusion. The microsatellite DNA polymorphism of AM ogy of renal diseases.
gene may be associated with the genetic predisposition to de- With regard to the genetic background of renal dis-
velop nephropathy in Japanese patients with type 2 diabetes eases, it has been demonstrated that diabetic nephropa-
mellitus. thy, not only type 1 but also type 2, occurs in familial
clusters, suggesting that genetic factors may be involved
in the pathogenesis [13, 14]. In this aspect, numbers of
studies have been performed as to the association of
various gene polymorphisms with genetic susceptibilityKey words: adrenomedullin, gene polymorphism, diabetes mellitus,
diabetic nephropathy, microsatellite repeats, genetic markers. to suffer diabetic nephropathy. In the present study, we
investigated the relationship between the microsatelliteReceived for publication September 26, 2002
DNA polymorphism adjacent to the AM gene and ge-and in revised form November 30, 2002
Accepted for publication January 28, 2003 netic predisposition to develop nephropathy in Japanese
type 2 diabetic patients. 2003 by the International Society of Nephrology
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METHODS was performed with 0.5 g of genomic DNA and 25 pmol
of each primer (sense 5-AAGAGGCTGAGTCAGAAStudy subjects
GGATTGG-3 and antisense 5-GCAACATCATTTT
A group of 139 hemodialysis patients with type 2 dia- AATATCCTGCACAG-3) in a final volume of 50 L
betes (DM-HD) were selected from the hemodialysis containing 10 mmol/L Tris-HCl (pH 8.3), 50 mmol/L
unit of Dokkyo University School of Medicine Hospital KCl, 1.5 mmol/L MgCl2, 10 g/mL gelatin, 0.2 mmol/Land eight nearby hemodialysis hospitals and clinics. of each deoxynucleoside triphosphate (dNTP), 1 unit of
Type 2 diabetes was diagnosed when diabetes was de- Taq DNA polymerase (Perkin-Elmer, Branchburg, New
tected at 30 years old or older and insulin therapy was Jersey). The 5 end of sense primer was labeled with the
not given during 2 years after the onset [15]. From the blue fluorescent dye 6-FAM. The DNA was amplified
same hospitals and clinics, 318 hemodialysis patients due for 30 cycles with denaturation at 94C for 45 seconds,
to chronic glomerulonephritis (CGN-HD) were involved annealing at 60C for 1 minute, and extension at 72C
in this study. Glomerulonephritis was diagnosed by pre- for 2 minutes in a thermal cycler. Then, an aliquot of the
vious renal biopsy or the presence of 2 or more protein- PCR product was mixed with the internal DNA size
uria and hematuria and exclusion of other renal diseases standard labeled with the red fluorescent dye ROX. The
such as diabetic nephropathy, hypertensive nephrosclero- mixture was electrophoresed on a 6% urea-polyacryl-
sis, lupus nephritis, polycystic kidney, and pyelonephritis. amide gel using ABI 373 DNA sequencer (Perkin-Elmer).
A hundred and six control type 2 diabetes patients without The length of PCR product was calculated from the cali-
nephropathy (DM-C) were selected from the outpatient bration curve of internal standard using GENESCAN
clinic of Dokkyo University School of Medicine Hospi- 672 software (Perkin-Elmer).
tal. In addition to the criteria for the diagnosis of type 2
diabetes, three more criteria were applied to select DM-C Biochemical measurement
subjects: (1) normal serum creatinine (men 1.5 mg/dL Peripheral blood sample was obtained in the morning
and women 1.3 mg/dL), (2) absence of microalbumin- after overnight fast in NH and DM-C. In DM-HD and
uria, and (3) 5 or more years of known history of diabetes. CGN-HD, blood sample was taken before hemodialysis.
Microalbuminuria was denied when the albumin in spot Serum creatinine was measured by automatic analyzer
urine was less than 30 mg/g creatinine on multiple occa- (HITACHI 736-60; Hitachi, Tokyo, Japan) and blood
sions [16]. The normal healthy group (NH) included 233 hemoglobin A1c was determined by high-performance
healthy subjects age 50 years old or older. They were re- liquid chromatography (HPLC) using ADAMS hemo-
cruited from participants of the health check program globin A1c HA-8160 (ARKRAY, Inc., Kyoto, Japan).
of Dokkyo University School of Medicine Hospital. Dis-
eases were ruled out through comprehensive checkup, in- Statistical analysis
cluding a full medical history taking and physical exami- Data are presented as means SD. Statistical analyses
nations, urinalysis, a stool examination, blood cell counts, were performed using Stat View software (version 5.0;
blood chemistry, a glucose tolerance test, serologic tests SAS Institute Inc., Cary, NC, USA). Clinical characteris-
for hepatitis viruses, a chest x-ray film, an electrocardio- tics between the case and control groups were compared
gram, a respiratory function, an alimentary examination by one-way analysis of variance (ANOVA) for paramet-
of the upper gastrointestinal tract, and abdominal ultra- ric data and by chi-square test for categoric data. If the
sonography. The physical examination was performed by ANOVA showed statistical significance, Scheffe’s test
an internist, a surgeon, an ophthalmologist, an otorhino- was applied for the post-hoc comparison between groups.
laryngologist, and a gynecologist for women. All subjects The frequencies of alleles and genotypes in the four
were Japanese and unrelated each other. groups were compared by chi-square test and Fisher’s
The study protocol was approved by the Institutional exact test. Differences of parametric data in two groups
Ethical Committee, and informed consent was obtained were analyzed by unpaired Student t test. A P value less
from each subject. than 0.05 was considered to indicate statistical signifi-
cance.
Genotype analysis
The number of CA repeats adjacent to AM gene was
RESULTSdetermined by fluorescence-labeled polymerase chain
Clinical characteristics of study subjectsreaction and polyacrylamide gel electrophoresis (PCR-
PAGE) as described previously [12, 17]. Genomic DNA Table 1 lists the physical and laboratory findings of
was extracted from peripheral leukocytes using Easy the study subjects. Average age and the gender ratio
DNA kit (Invitrogen, Carlsbad, CA, USA). The micro- were not significantly different among the four groups.
satellite region containing the CA repeats 4 kb down- Body mass index was greater in DM-C than in NH (P 
0.026). However, the body mass index of DM-HD wasstream of the AM gene was amplified by PCR. The PCR
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Table 1. Clinical characteristics of the study subjects
NH DM-C DM-HD CGN-HD
Parameter N  233 N  106 N  139 N  318
Age years 576 5916 6010 5712
Sex male/female 154/79 64/42 93/46 184/134
Body mass index kg/m2 23.72.8 24.94.2a 21.12.8b,d 20.72.7b
Systolic blood pressure mm Hg 11711 14625b 16415b,d,e 15319b
Diastolic blood pressure mm Hg 738 8515b 818b,c 819b
Duration of diabetes years 146 157
(until nephropathy was revealed) (86)
Duration of dialysis years 53e 96
Serum creatinine mg/dL 0.90.1 1.00.2 10.32.9b,d,e 11.92.7b
Blood hemoglobin A1c 9.52.3 6.71.6d
Abbreviations are: NH, normal healthy subjects; DM-C, control diabetic patients without nephropathy; DM-HD, diabetic patients on hemodialysis; CGN-HD,
hemodialysis patients due to chronic glomerulonephritis. Data are mean  SD. F values of ANOVA for body mass index, systolic blood pressure, diastolic blood
pressure, and serum creatinine are 72.0 (P  0.001), 250.4 (P  0.001), 48.7 (P  0.001), and 1422.8 (P  0.001), respectively.
a P  0.01; b P  0.001 vs. NH; c P  0.01; d P  0.001 vs. DM-C; and e P  0.001 vs. CGN-HD
Table 3. Allele frequencies of microsatellite DNA polymorphismTable 2. Genotype frequencies of microsatellite DNA
polymorphism adjacent to the human adrenomedullin adjacent to the human adrenomedullin gene in the study subjects
gene in the study subjects
NH DM-C DM-HD CGN-HD
Allele N  233 N  106 N  139 N  318Genotype NH DM-C DM-HD CGN-HD
N (%) N  233 N  106 N  139 N  318
11 CA repeats 27.7% 28.8% 31.6% 27.8%
13 CA repeats 32.8% 37.3% 27.8% 33.7%11/11 22 (9.4%) 8 (7.6%) 14 (10.0%) 18 (5.7%)
11/13 44 (18.9%) 19 (17.9%) 30 (21.6%) 54 (17.0%) 14 CA repeats 35.6% 29.7% 31.6% 34.6%
19 CA repeats 3.9% 4.2% 9.0%a 3.9%11/14 37 (15.9%) 23 (21.7%) 24 (17.3%) 76 (23.9%)
11/19 4 (1.7%) 3 (2.8%) 6 (4.3%) 11 (3.4%) Abbreviations are: NH, normal healthy subjects; DM-C, control diabetic pa-
13/13 23 (9.9%) 20 (18.9%) 8 (5.8%) 36 (11.3%) tients without nephropathy; DM-HD, diabetic patients on hemodialysis; CGN-
13/14 54 (23.2%) 17 (16.1%) 22 (15.8%) 81 (25.5%) HD, hemodialysis patients due to chronic glomerulonephritis.
13/19 9 (3.9%) 3 (2.8%) 9 (6.5%) 7 (2.2%) a2  18.9, P  0.026
14/14 35 (15.0%) 10 (9.4%) 16 (11.5%) 28 (8.8%)
14/19 5 (2.1%) 3 (2.8%) 10 (7.2%) 7 (2.2%)
19/19 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
11, 13, 14, and 19. The alleles with 11, 13, 14, and 19 CA
Abbreviations are: NH, normal healthy subjects; DM-C, control diabetic pa-
repeat yield DNA fragment length of 248, 252, 254, andtients without nephropathy; DM-HD, diabetic patients on hemodialysis; CGN-
HD, hemodialysis patients due to chronic glomerulonephritis. 264 bp, respectively. Combination of the four alleles
yields ten possible genotypes: 11/11, 11/13, 11/14, 11/19,
13/13, 13/14, 13/19, 14/14, 14/19, and 19/19. Table 2 showssmaller than that of NH and comparable to that of
observed frequencies of these ten genotypes of this mi-CGN-HD. Systolic and diastolic blood pressures were
crosatellite gene polymorphism in the study subjects, andobviously higher in DM-C, DM-HD, and CGN-HD than
Table 3 lists the frequency of each allele calculated fromin NH (P  0.001, respectively). Especially, DM-HD
the genotype frequencies. The genotype frequencies werehad even higher systolic blood pressure than DM-C and
not significantly deviated from those expected from theCGN-HD (P  0.001, respectively), and DM-C had
Hardy-Weinberg’s equilibrium in each group. The fre-higher diastolic pressure than DM-HD (P  0.007) and
quencies of 11, 13, and 14, repeat alleles were approxi-CGN-HD (P  0.008). Duration of diabetes was compa-
mately 30%, while the frequency of 19 repeat allele wasrable between DM-C and DM-HD, however, the dura-
less than 10% in each group. There were no homozygotestion of diabetes in DM-C was longer than the duration
of the least frequent 19 repeat allele in the examinedof diabetes until nephropathy was revealed in DM-HD,
subjects. Distributions of the genotypes were not signifi-P 0.001. In hemodialysis patients, DM-HD had shorter
cantly different among the four groups. On the other hand,duration of dialysis than CGN-HD, P  0.001. Serum
creatinine did not significantly differ between NH and the allele frequencies were significantly different between
DM-C. Of course, DM-HD and CGN-HD had much the groups (2  18.9, P  0.026). Figure 1 depicts the dif-
higher serum creatinine than NH and DM-C (P  0.001, ference in allele frequency more clearly. The frequency
respectively). In hemodialysis patients, predialysis serum of 19 repeat allele was higher in DM-HD than in NH,
creatinine was lower in DM-HD than in CGN-HD, P  DM-C, or CGN-HD. The frequencies of 11, 13, and 14
0.001. Blood hemoglobin A1c was lower in DM-HD than repeat alleles did not show significant group differences.
in DM-C, P  0.001.
DISCUSSIONGenotype and allele frequencies
Nowadays, diabetic nephropathy is the leading causeAs we have reported previously [12, 17], there existed
four types of alleles with different CA repeat number; of end-stage renal failure in Japan as well as in United
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DNA polymorphism adjacent to the AM gene with the
genetic predisposition to suffer diabetic nephropathy.
Namely, the existence of 19 CA repeat allele is supposed
to be associated with the risk of developing nephropathy
in Japanese type 2 diabetic patients. However, because
the frequency of this 19 repeat allele was small, this gene
variation alone is not thought to reflect the large part
of genetic predisposition to diabetic nephropathy. Any
single gene polymorphism, which has been previously
shown to be associated with diabetic nephropathy, does
not represent the large part of genetic risk for diabetic
nephropathy. It is supposed that multiple genes contrib-
ute to the development of diabetic nephropathy. In the
future direction, information as to the relation between
gene polymorphisms and the risk of diabetic nephropa-
thy should be gathered and analyzed comprehensivelyFig. 1. Frequencies of 11, 13, 14, and 19 repeat alleles in normal healthy
subjects (NH), control diabetic subjects without nephropathy (DM-C), to construct a way to evaluate the genetic risk of diabetic
diabetic patients on hemodialysis (DM-HD), and hemodialysis patients nephropathy precisely. In this sense, The DNA polymor-
due to chronic glomerulonephritis (CGN-HD). *P  0.05; **P  0.01.
phism examined in this study seems to add information
to the prediction of the development of diabetic ne-
phropathy.
Some gene polymorphisms have been shown to affectStates and European countries. Because type 2 diabetes
expression of the genes or activity of the gene products.is much more frequent than type 1 diabetes in Japan,
For instance, the serum ACE activity is known to beprevention of nephropathy in type 2 diabetic patients is
increased in individuals carrying the deletion allele ofof primary importance. In order to reduce the incidence
the gene [28], and it has been reported that the methio-of diabetic nephropathy effectively, it is necessary to
nine to threonine substitution at amino acid residue 235identify the patients at high risk. It is known that the
(M235T) of angiotensinogen is associated with an in-influence of a genetic factor on the onset of diabetes is
crease in the gene expression [29]. Because the micro-greater in type 2 diabetes than in type 1 diabetes. Al-
satellite polymorphism examined in this study is locatedthough the familial clustering of diabetic nephropathy
3 downstream of the AM gene, it is unlikely that thehas first been reported in type 1 diabetes [13], later evi-
gene transcription is affected by this polymorphism. In-dence has also indicated inherited susceptibility to ne-
deed, the plasma AM levels were not significantly differ-phropathy in type 2 diabetes [14, 18, 19]. In order to
ent among the genotypes of this polymorphism in normaldelineate the genetic background of type 2 diabetic ne-
subjects [12]. Namely, the subjects carrying 19 repeatphropathy, numbers of studies have investigated the as-
allele and the homogygotes of 11, 13, and 14 repeat allelesociation of this complication with various gene polymor-
showed comparable plasma AM levels. Therefore, thephisms. So far, several gene polymorphisms have been
association of 19 CA repeat allele with diabetic nephrop-indicated to have relation with the predisposition to de-
athy is not likely mediated by the gene expression andvelop nephropathy in type 2 diabetic patients. The gene
the action of AM itself. It may be possible that thispolymorphisms include genes of renin-angiotensin sys-
microsatellite polymorphism is associated with the ex-tem such as angiotensin-converting enzyme (ACE) and
pression of other genes. Near the location of AM geneangiotensinogen, and genes of endothelial nitric oxide
in the short arm of chromosome 11, there exist suchsynthase, glucose transporter, apolipoprotein E, methyl-
genes as sphyngomyelinase, parathyroid hormone, andenetetrahydrofolate reductase and G-protein 	3 subunit
[20–27]. lactate dehydrogenase [30–32]. Among these, so far the
literature does not suggest relation of sphyngomyelinaseIn the present study, we examined the microsatellite
DNA polymorphism lying 3 downstream of the AM and lactate dehydrogenase genes to diabetic nephropa-
thy. With regard the parathyroid hormone gene, it hasgene in diabetic patients and patients with end-stage
renal disease. Among the four types of alleles with CA been shown that the secretion of parathyroid hormone
is impaired in patients with diabetic nephropathy [33, 34],repeat number of 11, 13, 14, and 19, the frequency of 19
repeat allele was higher in DM-HD than in NH, DM-C, which suggests relation between the development of dia-
betic nephropathy and the expression of parathyroid hor-and CGN-HD. The frequency of 19 repeat allele in
DM-HD was more than twice as much as other groups. mone gene, although this may be caused by the long du-
ration of poor glycemic control as well. Besides these,This result suggests the association of microsatellite
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the microsatellite polymorphism downstream of AM gene 24–26, 42, 44–46]. In this respect, the subjects of this study
are all Japanese and ethnically unanimous. However,may be linked to other yet unidentified gene variations.
Microsatellite markers, like the one examined in this inharmonious results have been sometimes obtained
even in the same or the closely related ethnic groupsstudy, consist of variable number of repeats of short
nucleotides, and more than hundreds of such repeat [23, 27, 43, 47]. In some studies, microalbuminuria was
assumed to indicate the existence of diabetic nephropa-markers are scattered throughout the genomic DNA.
These microsatellite markers can be utilized to locate thy. However, it has been reported that type 2 diabetic
patients with microalbuminuria have heterogenous renalthe genomic region responsible for hereditary diseases
or traits. Until now, several diseases have been shown lesions [48]. Therefore, the relations between gene poly-
morphisms and type 2 diabetic nephropathy may be af-to be associated with such microsatellite DNA polymor-
phism. For instance, it has been reported that the CA fected by the criteria used for the diagnosis of diabetic
nephropathy.repeat polymorphism lying upstream of aldose reductase
gene affects the development of nephropathy and reti- The results of this study revealed the association of
the microsatellite CA repeat polymorphism adjacent tonopathy in type 1 diabetes mellitus [35, 36]. However,
inconsistent results have been reported as to the associa- the AM gene with genetic predisposition to type 2 dia-
betic nephropathy in Japanese population. The frequencytion of this microsatellite polymorphism with type 2 dia-
betic nephropathy [37–39]. On the other hand, genetic of 19 repeat allele was significantly increased in patients
with end-stage renal disease due to type 2 diabetes. Al-predisposition to essential hypertension has been shown
to have significant linkage to a certain number of TCAT though this DNA polymorphism is not likely to affect
the AM gene transcription, the existence of 19 CA repeatrepeat in the intron 1 of tyrosine hydroxylase gene and
the GT repeat in the intron 2 of type B natriuretic peptide allele is supposed to reflect a certain part of the genetic
predisposition to develop nephropathy in Japanese typereceptor gene [40, 41]. We have also reported that the
19 CA repeat allele examined in this study is increased 2 diabetic patients.
in patients with essential hypertension [17]. The relation
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